FLT3 and acute myeloid leukemia: The Cancer and Leukemia Group B (CALGB) 10,603 RATIFY trial was a multi-institutional, multinational, randomized, double-blind placebo-controlled trial that examined the effects of adding midostaurin to standard chemotherapy in adults aged 18–59 years old with newly diagnosed AML and an FLT3 mutation.